22 peptides tracked
Australia's
Independent
Peptide Register
No vendors. No affiliates. Just data.
Fig. 01
Regulatory Status · May 2026
Retatrutide2
GHK-Cu10
Semaglutide12
Tirzepatide8
BPC-15718
CJC-129515
22
Peptides tracked
40
Prescription providers
52
Observed suppliers
1
Prohibited (S9)
01Intelligence
Peptide Status
TGA scheduling, enforcement trends, and access pathways for each peptide. Updated August 2026.
Editorial position: We recommend accessing peptides through an AHPRA-registered medical practitioner and TGA-licensed compounding pharmacy. This ensures clinical oversight, pharmaceutical-grade compounding, and legal compliance.
Retatrutide
Triple Agonist (GLP-1/GIP/Glucagon)
GHK-Cu
Copper Peptide
Semaglutide
GLP-1 Agonist
Tirzepatide
GLP-1/GIP Agonist
BPC-157
Tissue Repair
CJC-1295
Growth Hormone Secretagogue
Ipamorelin
Growth Hormone Secretagogue
TB-500
Tissue Repair
Melanotan II
Melanocortin Agonist
PT-141 (Bremelanotide)
Melanocortin Agonist
MOTS-c
Mitochondrial Peptide
Thymosin Alpha-1
Immune Modulator
KPV
Anti-inflammatory Peptide
Epithalon
Telomerase Activator
Gonadorelin
Hormonal Support
Dihexa
Cognitive Enhancement
02News
Regulatory Feed
Latest scheduling changes, enforcement actions, and market developments across all tracked peptides.
HeadlineSourceDate
Retatrutide effects on diabetic rats' cognitionRetatrutide
Lab animal1 Aug 2026Semaglutide improves MASLD and MASH in people with HIV: The SLIM LIVER studySemaglutide
HIV Medicine28 July 2026Dose-dependent effects of oral semaglutide on arterial stiffness and the additive role of SGLT-2 inhibitors in type 2 diabetesSemaglutide
British Journal of Clinical Pharmacology28 July 2026Semaglutide for low back pain trial posted on ClinicalTrials.govSemaglutide
ClinicalTrials.gov28 July 2026Effects of semaglutide on brain dopamine responses to food cues in adults with obesity and food addiction tendencies trial posted on ClinicalTrials.govSemaglutide
ClinicalTrials.gov28 July 2026Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matricesBPC-157
Analyst27 July 2026Trends in publicly subsidized and private access to GLP-1 medicines indicated for type 2 diabetes in Australia, 2020–2025Semaglutide
British Journal of Clinical Pharmacology27 July 2026Impact of semaglutide withdrawal on cardiometabolic profile and physiology of energy balance: The REST trial study protocolSemaglutide
PLOS One27 July 2026Semaglutide and other GLP-1 agonists for antipsychotic-associated metabolic dysfunction in schizophrenia: A systematic review and meta-analysisSemaglutide
Journal of Clinical Psychopharmacology27 July 2026Accidental intradermal injection of tirzepatide associated with increased adverse eventsTirzepatide
Postgraduate Medical Journal27 July 2026Topical-lingual semaglutide in adults with obesity proof-of-concept trial posted on ClinicalTrials.govSemaglutide
ClinicalTrials.gov27 July 2026Preoperative semaglutide before radical prostatectomy trial posted on ClinicalTrials.govSemaglutide
ClinicalTrials.gov27 July 2026Once-weekly tirzepatide in patients with obesity and type 2 diabetes trial posted on ClinicalTrials.govTirzepatide
ClinicalTrials.gov27 July 2026Efficacy and safety of once-weekly semaglutide 2.0 mg added to dose-reduced insulin glargine versus dose-titrated insulin glargine in type 2 diabetes and overweightSemaglutide
Diabetes, Obesity and Metabolism26 July 2026Cost-effectiveness of semaglutide 2.4 mg and resmetirom versus standard care for metabolic dysfunction-associated steatohepatitisSemaglutide
PharmacoEconomics26 July 2026Efficacy of CagriSema for reaching anthropometric treatment targets and cardiometabolic outcomes: A secondary analysis of REDEFINE 1Semaglutide
Diabetes, Obesity and Metabolism26 July 2026Severe hypercalcemia in a patient taking tirzepatide: Potential risk factorsTirzepatide
Cureus26 July 2026Rare eye disorder linked to Ozempic-like medicationsSemaglutide
ABC News Australia24 July 2026Australian regulator TGA warns of rare but severe eye disorder linked to GLP-1 drugs like OzempicSemaglutide
The Guardian24 July 2026Semaglutide and tirzepatide linked to fewer alcohol-related hospital visitsTirzepatide
News-Medical24 July 2026Regulatory Notice
For informational purposes only. TGA scheduling may change without notice. All Schedule 4 peptides require a valid prescription from a registered Australian medical practitioner. This site does not sell, supply, or facilitate access to therapeutic goods. Data compiled from TGA SUSMP, public provider directories, and publicly available review platforms.